Beam Therapeutics tops Q4 profit estimates, signs financing deal

Beam Therapeutics

24/02/2026 12:10

Overview

Biotechnology firm reported Q4 EPS and net income beat analyst expectations

Company entered strategic financing agreement with Sixth Street for up to $500 mln

Company expanded liver-targeted genetic disease franchise with BEAM-304 for PKU

Outlook

Beam expects to file IND for BEAM-304 in 2026

Beam plans BLA submission for risto-cel by year-end 2026

Beam anticipates updated BEAM-302 data by Q1 2026

Result Drivers

BEAM-304 EXPANSION - Beam expanded its liver-targeted genetic disease franchise with BEAM-304 for PKU, leveraging base editing technology to address mutations in the PAH gene

STRATEGIC FINANCING - Beam secured a strategic financing agreement with Sixth Street for up to $500 mln to support the launch of risto-cel in SCD

Company press release: ID:nGNX2YX5lq

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 License and Collaboration Revenue
$114.11 mln
Q4 EPS
Beat
$2.33
-$0.99 (15 Analysts)
Q4 Net Income
Beat
$244.30 mln
-$91.17 mln (15 Analysts)
Q4 Operating Income
Beat
-$17.45 mln
-$117.30 mln (14 Analysts)
Q4 Pretax Profit
Beat
$244.30 mln
-$95.99 mln (13 Analysts)
Q4 Operating Expenses
$131.55 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Beam Therapeutics Inc is $45.00, about 58.8% above its February 23 closing price of $28.33

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)